 PARIS and CAMBRIDGE, Mass., March 22, 2021 GLOBE NEWSWIRE -- BIOPHYTIS SA Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS, BIOPHYTIS or the company, a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, announces that the independent Data Monitoring Committee DMC for the COVA study has delivered a favorable opinion on the safety of Sarconeos BIO101 in patients infected with COVID-19, following the scheduled interim analysis of the 50 participants from Part 1 of the study, as well as the progression of patients enrollment, which has now reached 97 of the 155 planned for the second interim analysis. 